413 related articles for article (PubMed ID: 29026972)
21. Improved management of abdominal undescended testicular tumors with bulky confluent retroperitoneal nodal metastases.
Kulkarni JN; Desai SM; Phadke GK; Tongaonkar HB
J Urol; 1996 Oct; 156(4):1341-4. PubMed ID: 8808867
[TBL] [Abstract][Full Text] [Related]
22. Survival analysis of pure seminoma at post-chemotherapy retroperitoneal lymph node dissection.
Rice KR; Beck SD; Bihrle R; Cary KC; Einhorn LH; Foster RS
J Urol; 2014 Nov; 192(5):1397-402. PubMed ID: 24813309
[TBL] [Abstract][Full Text] [Related]
23. Robot-assisted Laparoscopic Retroperitoneal Lymph Node Dissection for Testicular Cancer: Evolution of the Technique.
Stepanian S; Patel M; Porter J
Eur Urol; 2016 Oct; 70(4):661-667. PubMed ID: 27068395
[TBL] [Abstract][Full Text] [Related]
24. Postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumours of the testis.
Heidenreich A; Thüer D; Polyakov S
Eur Urol; 2008 Feb; 53(2):260-72. PubMed ID: 18045770
[TBL] [Abstract][Full Text] [Related]
25. Laparoscopic RPLND for clinical stage I nonseminomatous germ cell testicular cancer: current status.
Bhayani SB; Allaf ME; Kavoussi LR
Urol Oncol; 2004; 22(2):145-8. PubMed ID: 15082014
[TBL] [Abstract][Full Text] [Related]
26. Treatment of a population based sample of men diagnosed with testicular cancer in the United States.
Osswald M; Harlan LC; Penson D; Stevens JL; Clegg LX
Urol Oncol; 2009; 27(6):604-10. PubMed ID: 18799329
[TBL] [Abstract][Full Text] [Related]
27. Lymph node count impacts survival following post-chemotherapy retroperitoneal lymphadenectomy for non-seminomatous testicular cancer: a population-based analysis.
Bhanvadia RR; Rodriguez J; Bagrodia A; Eggener SE
BJU Int; 2019 Nov; 124(5):792-800. PubMed ID: 31054211
[TBL] [Abstract][Full Text] [Related]
28. Retroperitoneal Lymph Node Dissection in Clinical Stage IIA/B Metastatic Seminoma: Results of the COlogne Trial of Retroperitoneal Lymphadenectomy In Metastatic Seminoma (COTRIMS).
Heidenreich A; Paffenholz P; Hartmann F; Seelemeyer F; Pfister D
Eur Urol Oncol; 2024 Feb; 7(1):122-127. PubMed ID: 37438222
[TBL] [Abstract][Full Text] [Related]
29. National management trends in clinical stage IIA nonseminomatous germ cell tumor (NSGCT) and opportunities to avoid dual therapy.
Labbate CV; Werntz RP; Galansky LB; Packiam VT; Eggener SE
Urol Oncol; 2020 Aug; 38(8):687.e13-687.e18. PubMed ID: 32305267
[TBL] [Abstract][Full Text] [Related]
30. Patterns of care and survival outcomes for adolescent and young adult patients with testicular seminoma in the United States: A National Cancer Database analysis.
Stokes W; Amini A; Maroni PD; Kessler ER; Stokes C; Cost CR; Greffe BS; Garrington TP; Liu AK; Cost NG
J Pediatr Urol; 2017 Aug; 13(4):386.e1-386.e7. PubMed ID: 28153774
[TBL] [Abstract][Full Text] [Related]
31. Long-term results of laparoscopic retroperitoneal lymph node dissection: a single-center 10-year experience.
Steiner H; Peschel R; Janetschek G; Höltl L; Berger AP; Bartsch G; Hobisch A
Urology; 2004 Mar; 63(3):550-5. PubMed ID: 15028456
[TBL] [Abstract][Full Text] [Related]
32. Postchemotherapy laparoscopic retroperitoneal lymph node dissection for low-volume, stage II, nonseminomatous germ cell tumor: first 100 patients.
Steiner H; Leonhartsberger N; Stoehr B; Peschel R; Pichler R
Eur Urol; 2013 Jun; 63(6):1013-7. PubMed ID: 23021090
[TBL] [Abstract][Full Text] [Related]
33. Current controversies on the role of retroperitoneal lymphadenectomy for testicular cancer.
Mano R; Di Natale R; Sheinfeld J
Urol Oncol; 2019 Mar; 37(3):209-218. PubMed ID: 30446455
[TBL] [Abstract][Full Text] [Related]
34. Laparoscopic retroperitoneal lymph-node dissection in the management of clinical stage I and II testicular cancer.
Albqami N; Janetschek G
J Endourol; 2005; 19(6):683-92; discussion 692. PubMed ID: 16053357
[TBL] [Abstract][Full Text] [Related]
35. Management of testicular seminoma advanced disease. Report on 14 cases and review of the literature.
Porcaro AB; Antoniolli SZ; Maffei N; Beltrami P; Bassetto MA; Curti P
Arch Ital Urol Androl; 2002 Jun; 74(2):81-5. PubMed ID: 12161942
[TBL] [Abstract][Full Text] [Related]
36. Trends of retroperitoneal lymphadenectomy use in patients with nonseminomatous germ cell tumor of the testis: a population-based study.
Sun M; Abdollah F; Budaüs L; Liberman D; Tian Z; Morgan M; Johal R; Schmitges J; Shariat SF; Montorsi F; Greafen M; Perrotte P; Karakiewicz PI
Ann Surg Oncol; 2011 Oct; 18(10):2997-3004. PubMed ID: 21509630
[TBL] [Abstract][Full Text] [Related]
37. Retroperitoneal lymph node dissection for high-risk stage I and stage IIA seminoma.
Mezvrishvili Z; Managadze L
Int Urol Nephrol; 2006; 38(3-4):615-9. PubMed ID: 17111085
[TBL] [Abstract][Full Text] [Related]
38. Role of primary retroperitoneal lymph node dissection in stage I and low-volume metastatic germ cell tumors.
Heidenreich A; Paffenholz P; Nestler T; Pfister D; Daneshmand S
Curr Opin Urol; 2020 Mar; 30(2):251-257. PubMed ID: 31972635
[TBL] [Abstract][Full Text] [Related]
39. Risk of Recurrence for Clinical Stage I and II Patients With Teratoma Only at Primary Retroperitoneal Lymph Node Dissection.
Liu NW; Cary C; Strine AC; Beck SD; Masterson TA; Bihrle R; Foster RS
Urology; 2015 Nov; 86(5):981-4. PubMed ID: 26232690
[TBL] [Abstract][Full Text] [Related]
40. The role of primary retroperitoneal lymph node dissection in the treatment of stage II seminoma.
Sigg S; Fankhauser CD
Curr Opin Urol; 2023 Jul; 33(4):245-251. PubMed ID: 37144886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
